Hengrui Pharma announced that it has reached an agreement with biopharmaceutical company GSK to grant paid licenses to GSK for the global exclusive rights of the HRS-9821 project (excluding mainland China, Hong Kong SAR, Macau SAR, and Taiwan) and the exclusive option for the global exclusive license of up to 11 projects.
GSK will pay Hengrui $500 million as an initial payment. If all projects are granted exclusive options and all milestones are achieved, Hengrui will be eligible to receive a potential total amount of around $12 billion based on successful development, registration, and sales milestone payments.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。